Actively Recruiting
Secondary Central Nervous System Lymphoma Registry - Charité
Led by Charite University, Berlin, Germany · Updated on 2023-11-27
300
Participants Needed
1
Research Sites
782 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of the observation is to collect and document data on treatment strategies for secondary central nervous system lymphoma (SCNSL) in routine clinical practice, whether obtained in the context of clinical trials or outside of trials. In particular, the following questions will be specified: * What therapeutic approaches are being pursued? * What is the clinical outcome of the various treatment options? * What is the frequency of serious adverse events with each therapeutic approach?
CONDITIONS
Official Title
Secondary Central Nervous System Lymphoma Registry - Charité
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All patients with secondary central nervous system lymphoma (SCNSL) can participate regardless of treatment type or therapy stage (first-line, recurrence, or maintenance).
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Charité - Universitätsmedizin, Med. Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie (CBF)
Berlin, Germany, 12200
Actively Recruiting
Research Team
S
Stefan Habringer, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here